Barcode Diagnostics is a precision-medicine company developing a first-of-its-kind drug diagnostic tool for optimal personalized treatment. Using a unique nanoparticle delivery system, our product quickly and reliably assesses the efficacy of different cancer drugs directly on the tumor, within the body, to select the optimal treatment for each patient within 72 hours.
Ceretrieve Ltd. Is developing an innovative neuro-thrombectomy system with integrated embolic protection features that will safely and efficiently extract blood clots from large vessels in the brain and restore blood flow following an ischemic stroke. The Company’s next-generation aspiration catheter will improve clinical outcomes by securely removing the entire clot in one pass with the catheter’s proprietary large bore funnel and closure tip.
At densys3D we believe that 3D scanning should not be a luxury that only a few dentists’ can benefit from, but that every dentist should be able to enter the digital workflow. We’ve developed and are producing an affordable digital intraoral 3d scanner offering dentists quick scanning, fast processing, and real time immediate results with super high accuracy, offering more value than higher cost scanners. densys3D has just now started sales and are looking to raise funds for marketing / sales and the next generation product.
Everads Therapy Ltd. is developing a simple treatment approach - and novel delivery system - allows for highly effective delivery of therapies into the back of the eye addressing challenges in treatment of retinal diseases. Everads Therapy’s platform delivery system consists of a blunt injector for applying its unique access method to targeting the back of the eye. Everads technology (licensed from the Sheba Medical Center, Israel) demonstrated proof of concept through extensive preclinical studies.
Vaginitis is the most common feminine disorder and responsible for tens of millions of clinic visits. Currently, more than half are misdiagnosed by physicians, resulting with repeated visits, wrong treatment, health complications and huge redundant expenses. Led by experienced entrepreneurs, Gyntools Ltd developed the most comprehensive, accurate, rapid and affordable deep learning POC diagnostic tool for this multi-billion dollar market. GynTools secured a grant from the IIA, heading to clinical trials and ready now for an investment and strategic partners.
HT BioImaging is committed to save lives and improve the life quality of deadliest diseases patients. In order to do so, HT BioImaging has set to revolutionize early cancer detection. We developed a platform that lies at the base of a noninvasive, safe and highly accurate detection method. With our products, initial screening will become a simple and affordable process, easily accessed in the community. Our platform technology provides real-time results that will enable physicians to decide if additional, more expensive and high-risk testing is necessary – early on.
Plas-free is developing ClearPlasma, an innovative medical device, addressing the massive bleeding market. ClearPlasma is an extracorporal device that modifies human plasma to improve the treatment in patients suffering from massive bleeding. By efficiently removing fibrinolytic proteins, ClearPlasma decreases the activity of the endogenous fibrinolytic system and increases the efficiency of coagulation. We assume that patients transfused with ClearPlasma will show an increased capacity to form stable haemostaic clots, reduced bleeding tendency, thus potentially saving more lives.
PRC Biomedical Ltd. develops and disseminates beyond the state-of-the-art KIT Array that measures blood quality level for crucial applications as maximum storage period of donated blood unit and the right match of a blood unit to a specific patient prior to transfusion. The KIT addresses certain FDA requirements like minimum 75% survivability of the transfused RBC's after 24 hours and maximum storage period. The potential annual market is estimated at US$ 4 Billion and the company owns certain patents and other IP's.
Established in 2015 by Dr. SAHER Hamed, SEBANA Medical ltd. is a privately-held biopharmaceutical company whose aim is to develop a pharmaceutical product for preventing the absorption of a fat graft after dermal filling in soft tissue augmentation. The use of fat for dermal filling has advantages over the use of foreign materials such as silicone, hyaluronic acid and collagen. Sebana’s product is based on an active pharmaceutical ingredient which is a well-known and approved biologic that is being formulated for slow and sustained release during the critical period of fat resorption after dermal filling.
TiCure is a biotechnology company focused on dermatologic diseases. We discovered a novel protein as a target for drug intervention. We have found its involvement with several human skin diseases, both common and rare: Psoriasis, Skin Lymphoma, and others. All are chronic inflammatory diseases requiring continuous treatments, and some have no cure. After successfully achieving disease amelioration with an orally administered small molecule inhibitor, we moved to develop a topical, skin-penetrating drug therapy. We seek a strategic partner and investment.
Voyager is focused on the prevention of complex post-surgical complications. Our product is an Absorbable Surgical Suture with extended tensile strength of 4-5 months intended to reduce the incidence of POVH by as much as 50% with no extra cost to the hospital. In the US this decrease will save the lives of 17,000 patients annually and save the healthcare system $22.7B per year. The product is intended for use in every abdominal wall surgery, a business opportunity of $1.3B
Spinal fusion is one of the most common OR procedures performed in the United States, widely using pedicle screws that are invasive and encompass risk of misplacement. Zygofix has developed a uniquely designed miniature implant that achieves spinal fusion and spinal stability without screws. ZygoFix's innovative solution utilizes the natural construction of the spine to achieve optimum stability. Its implant is situated in the facet joints and results in a less invasive and simplified procedure.
RISING STARS SESSION - 5th October
AlephBot improves treatment efficiency, saves lives and reduces costs by capturing verbal communication and data from medical devices during medical procedures.
Taking into account medical guidelines and the patient’s records, the medical team receives valuable and relevant, real-time information, generated by applying AI to the captured data.
Moreover, the system auto-documents the procedures and creates medical records, thus providing risk management tool to hospitals and enabling accurate debriefing and constant improvement of teams. AlephBot first use case improves in-hospital resuscitation outcomes. This complies with regulations that promote novel methods for better patient safety. Additional use-cases will use the same platform.
Alibion is a pre-seed, Switzerland-based company (Basel area). Alibion was born to accelerate the development of therapeutics through early stages. Our efforts are focused on identifying promising, potential first-in-class/best-in-class therapeutics from academic laboratories and pooling the necessary resources to drive these compounds out of the labs and into late-stage development.
We have recently in-licensed our first candidate therapeutic for the treatment of Rheumatoid Arthritis from a top US university. The small molecule has already been successfully tested in animal models and is ready to proceed with IND enabling program.
Anaveon is developing next generation IL-2 pharmacological agents for tumor immunotherapy. Our approach is based on a highly selective antibody which re-directs IL-2 away from regulatory T cells to CD8 effector T cells. We have demonstrated robust efficacy in preclinical tumor models and a broad efficacy/safety window. The company has obtained seed financing and is currently raising Series A funding to allow completion of Ph I/II studies.
ARTIDIS has developed an innovative tool for accurate cancer diagnosis and treatment based on the power of nanotechnology. With the ARTIDIS platform we will improve patient’s lives by dramatically reducing the time it takes to accurately diagnose cancer – from a period of days or weeks to less than three hours, thereby substantially reducing anxiety and time lost. A faster and clearer ind ication based on precise measurements of cancer cell aggressiveness matched with big data paves the way for a personalized treatment and a more cost-effective and more successful therapy.
BioXplor is advancing intelligent and accelerated knowledge-based discovery in life science R&D to maximize the value of pharma assets, and ultimately improve patient outcomes. Our platform is designed for intelligent indication expansion and novel target ID.
Missing links in the biology of brain diseases (e.g., Alzheimer’s Disease, Depression, Epilepsy, Pain, Parkinson’s Disease and Schizophrenia) are the reason for ineffective treatments for the 1 in 10 people worldwide affected by these disorders. To address this problem, BRAINCURES has unraveled the molecular program behind learning and memory. This biological in telligence is captured in the BRAINCURES Discovery Engine, a unique platform tool that de-risks and accelerates drug discovery by turning your questions around compounds, diseases, data, AI-outputs and clinical trials into translational opportunities. The company is now working towards partnerships that enable better, safer and faster precision medicines.
Causaly is an AI for Biomedical Cause & Effect discovery, empowering researchers and decision makers to quickly find causal evidence and generate insights from vast amounts of documents. The company is developing a machine-reading platform that turns free-flow text into causal knowledge graphs and applies machine learning to surface new knowledge. This helps users to accelerate their research schedules and improve time-to-insight significantly.
Endotelix is a privately held Swiss biotech start-up company and a spin-off from the University of Geneva, focused on the diagnosis and treatment of Antiphospholipid Syndrome (APS).
APS is an autoimmune disease defined by the development of venous and/or arterial thromboses, often multiple, and high pregnancy morbidity. Endotelix has developed a fast, reliable and specific standardized solutions for clinical APS diagnostic tests.
Qnami develops new sensors based on quantum technologies. Our products allow our customers to perform non-invasive magnetic imaging at the nanoscale in all types of environment. Our solutions address the demand across different applications from fundamental material science to medical early-stage diagnostic.
Reactive Robotics develops robotic therapy solutions for intensive care units that semi-automate early mobilization. We simultaneously use robotics to automate therapy and collect data on patient therapy progress and recovery outcome.
We thereby enable hospitals to save one FTE nurse per robotic device, accelerate recovery of patients by an average of 20% as compared to the standard of care and provides doctors with recovery reports.
Extracting knowledge from single-cell data to save millions of lives. A new and emerging type of analytical devices are producing rich data-sets by measuring hundreds of parameters from millions of individual cells. The resulting single-cell data holds the information needed for early disease detection but it requires sophisticated and innovative computational approaches in order to extract the relevant information. We are addressing this problem by developing artificial intelligence (AI) software for single-cell data analysis. The underlying algorithms allow us to associate patterns in single-cell data with disease status, similar to how state-of-the-art methods for object recognition associate pixel patterns with objects. By partnering with hospitals to obtain single-cell patient data, we are building an AI-based pipeline for novel biomarker discovery, which will yield ultra-sensitive biomarkers for early and precise detection of a wide range of complex diseases. Further, we will provide a software solution, wrapping our AI technology for R&D customers from academia, pharma and clinics. By virtue of novelty and impact, our products have the potential to disrupt the healthcare market.
SpheroBiotics re-invents antibiotic discovery from nature. With a proprie tary microfluidic high-throughput platform, they tap the largely unharnessed potential of nature’s microbiomes. The technology combines access to hard-to-cultivate species with early-stage bioassays. SpheroBiotics focuses on the discovery of novel antibiotics for severe and life-threatening infectious diseases, in particular, multidrug-resistant pathogens, and aims to bring new life-saving medicines to patients. The pre-incorporation biotech startup from the ETH Zürich is based in Basel, Switzerland.
SunRegen is a typical entrepreneurial startup company operating an early-to-mid-stage drug development business. It has started the preclinical development of one key compound. The founder team of SunRegen has solid experiences in multinational companies and drug development. Four members in SunRegen scientific board are from big pharma, and each of them has over 30 years drug research experience. The intention of SunRegen is to develop this compound with least cost for the treatment of Amyotrophic lateral sclerosis (ALS).
Our compound is a small molecule. It can target the root cause of neurodegenerative and neuromuscular diseases. The strong effects of this compound were proven by 4 species, 10 neurotoxins, in more than 20 different models. Our test results have amazed every scientist who has seen them because this compound demonstrated remarkable neuroprotective, neurorescuing, antiapoptotic, neurotrophic, and axon-outgrowth effects.
TheraNASH is a start-up in creatio n for the development of first-in-class therapeutics for NASH, liver fibrosis and cancer. Liver disease and cancer are the only major cause of death still increasing each year with an untapped marked of up to 10 B$ per year. TheraNASH's pipeline is unique and different from competitors by the development of therapeutics targeting novel targets driving chronic liver disease, fibrosis and cancer. Furthermore, the TheraNASH program includes a companion biomarker and a unique drug discovery and development platform for liver disease therapeutics. The start-up program has raised seed funds and is currently completing a Series A.
Vasa- Advanced feminine hygiene products for women’s health, designed by women for women.
Women want a healthier, cleaner, natural choice.Reusable plant-based material, menstrual cups in three sizes made of 100% natural rubber.Vasa will be the only menstrual cups on the market that are - free of problematic ingredients such as silicone, plastics, chemicals, proteins, dyes or synthetics. Optimisation of material, design and addressing women’s hygiene concerns. Vasa is biodegradable and compostable vs. the current silicone-based cups (500-1’000 years to decompose). Cups can replace the 10-17’000 tampons & pads used in a woman’s lifetime.
The Vasa Wizard smart box (to be patented) sterilizes within 60 seconds (much easier, faster and more hygienic than current practice of ‘washing’). Wizard stores and tracks a woman’s cycle. The Vasa Wizard can assist in family planning, natural birth control and home diagnostics (such as for cell count). The Wizard can be used for all cup brands, is portable, worry-free cleaning and hygienic. Smart reporting of data via IPhone.Global market of ca. US$ 1 billion, Vasa gross margin above 70%. Vasa appeals to active, educated and health conscious women who recycle or look for ways to reduce waste. For use also in hospitals and doctor’s offices in menstrual blood analyses.
VisionHealth GmbH is a start-up based in Munich that supports patients with chronic lung diseases in living their lives without restriction. This is why VisionHealth is developing Kata®: An app that uses AI and machine learning to help patients to inhale effectively and at the right time according to their therapy regime. VisionHealth was founded by enthusiasts with extensive experience in developing products to ease therapy for patients with lung diseases. With Kata®, we bring the benefit of the digital health directly to the patients.